Marie Engvall

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia.

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia.

Journal: Blood advances

Published: April 04, 2025

Genetic Subtypes and Outcome of Patients Aged 1 to 45 Years Old With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial.

Genetic Subtypes and Outcome of Patients Aged 1 to 45 Years Old With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial.

Journal: HemaSphere

Published: February 08, 2023

Somatic Exonic Deletions in RUNX1 Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia.

Somatic Exonic Deletions in RUNX1 Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 14, 2023

Familial platelet disorder due to germline exonic deletions in RUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium.

Familial platelet disorder due to germline exonic deletions in RUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium.

Journal: Leukemia & lymphoma

Published: May 09, 2022

Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting.

Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting.

Journal: HemaSphere

Published: March 06, 2022

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

Journal: Leukemia

Published: March 05, 2022

Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.

Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.

Journal: British journal of haematology

Published: December 24, 2021

Cytogenetic aberrations in adult acute lymphoblastic leukemia-A population-based study.

Cytogenetic aberrations in adult acute lymphoblastic leukemia-A population-based study.

Journal: EJHaem

Published: July 05, 2021

Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.

Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.

Journal: Blood advances

Published: June 01, 2020

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.

Journal: British journal of haematology

Published: March 06, 2020

Detection of leukemia gene fusions by targeted RNA-sequencing in routine diagnostics.

Detection of leukemia gene fusions by targeted RNA-sequencing in routine diagnostics.

Journal: BMC medical genomics

Published: November 21, 2019

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.

Journal: British journal of haematology

Published: November 23, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026